{"id":"NCT01032629","sponsor":"Janssen Research & Development, LLC","briefTitle":"CANVAS - CANagliflozin cardioVascular Assessment Study","officialTitle":"A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12-09","primaryCompletion":"2017-02-22","completion":"2017-02-22","firstPosted":"2009-12-15","resultsPosted":"2018-12-07","lastUpdate":"2018-12-07"},"enrollment":4330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Risk Factors"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Canagliflozin (JNJ-28431754) 100 mg","otherNames":[]},{"type":"DRUG","name":"Canagliflozin (JNJ-28431754) 300 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Canagliflozin (JNJ-28431754) 100 mg","type":"EXPERIMENTAL"},{"label":"Canagliflozin (JNJ-28431754) 300 mg","type":"EXPERIMENTAL"}],"summary":"The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.\n\nThe data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.","primaryOutcome":{"measure":"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke","timeFrame":"Up to approximately 8 years","effectByArm":[{"arm":"Placebo","deltaMin":30.36,"sd":null},{"arm":"Canagliflozin 100 mg","deltaMin":28.41,"sd":null},{"arm":"Canagliflozin 300 mg","deltaMin":25.37,"sd":null},{"arm":"Canagliflozin (Total)","deltaMin":26.89,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.4576"},{"comp":"OG000 vs OG002","p":"=0.0467"},{"comp":"OG000 vs OG003","p":"0.1120"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":305,"countries":["United States","Argentina","Australia","Belgium","Canada","Colombia","Czechia","Estonia","France","Germany","Hungary","India","Israel","Luxembourg","Malaysia","Mexico","Netherlands","New Zealand","Norway","Poland","Russia","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["40689549","40239057","40105285","39844714","38932575","38770818","38240199","37671609","37543256","37345834","37149821","37120538","36443792","35938182","35724306","35115099","34876454","34448033","33826709","33595905","33158949","33121714","32971190","32694216","32691499","31399845","30882240","30591006","29941478","29937267","29693360","29526832","29133604","29103664","28605608","26580237","26121561","26081793","25468945","24786834","24517339","23895803"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":584,"n":1441},"commonTop":["Nasopharyngitis","Hypoglycaemia","Upper Respiratory Tract Infection","Back Pain","Urinary Tract Infection"]}}